MEDRX CO., LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112 JPY | -5.08% |
|
-5.08% | -25.83% |
| Sales 2022 | 59M 379K | Sales 2023 | 29M 186K | Capitalization | 5.79B 37.23M |
|---|---|---|---|---|---|
| Net income 2022 | -1.11B -7.14M | Net income 2023 | -932M -5.99M | EV / Sales 2022 | 28.3 x |
| Net cash position 2022 | 994M 6.39M | Net cash position 2023 | 1.72B 11.05M | EV / Sales 2023 | 140 x |
| P/E ratio 2022 |
-2.17
x | P/E ratio 2023 |
-5.63
x | Employees | 22 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.61% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.08% | ||
| 1 week | -5.08% | ||
| Current month | -19.42% | ||
| 1 month | -17.65% | ||
| 3 months | -37.08% | ||
| 6 months | -16.42% | ||
| Current year | -25.83% |
1 week
111.00
137.00
1 month
111.00141.00
Current year
111.00196.00
1 year
96.00320.00
3 years
91.00320.00
5 years
91.00643.00
10 years
91.002 518.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 02-01-14 | |
| President | 53 | 03-07-31 | |
Ken Fujioka
ADM | Chief Administrative Officer | 56 | 18-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 02-01-14 | |
| President | 53 | 03-07-31 | |
Keiko Yamasaki
BRD | Director/Board Member | 74 | 02-01-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 112 | -5.08% | 1,464,300 |
| 24-04-24 | 118 | +1.72% | 5,918,200 |
| 24-04-23 | 116 | -1.69% | 398,500 |
| 24-04-22 | 118 | +2.61% | 447,200 |
| 24-04-19 | 115 | -4.96% | 603,800 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -25.83% | 29.52M | |
| +4.16% | 70.78B | |
| +10.72% | 9.15B | |
| -17.03% | 4.84B | |
| +37.51% | 4.22B | |
| +3.92% | 3.92B | |
| +18.14% | 2.55B | |
| -24.13% | 2.26B | |
| -29.70% | 2.24B | |
| +9.09% | 1.92B |
- Stock Market
- Equities
- 4586 Stock
